(March 3, 2017, 7:15 AM EST) -- WASHINGTON, D.C. — In a Feb. 10 opening brief in its high-stakes suit with Amgen Inc., Sandoz Inc. argues that the Federal Circuit U.S. Court of Appeals erred by forcing biosimilar makers to get approval before supplying 180-day notice of sales to rivals because permitting notice before approval is consistent with “early resolution of patent disputes” (Sandoz Inc. v. Amgen Inc. and Amgen Manufacturing Ltd., No. 15-1039, U.S. Sup.)....